China Forum on Ethical Business Practices for Pharmaceutical Industry Held in Beijing




[May 27, 2014, Beijing] To further promote the  implementation of the Ethical Codes for Pharmaceutical Companies (hereinafter the  Codes), strengthen the building of the industry’s credit system, actively  execute industry-based disciplines and create an orderly, fair environment for  competition and a self-regulatory platform for the industry, China  Pharmaceutical Industry Association, China Chamber of Commerce for Import &  Export of Medicines & Health Products, China Pharmaceutical Industry  Research and Development Association, R&D-based Pharmaceutical Association  Committee under China Association of Enterprises with Foreign Investment  (RDPAC), China Association of Traditional Chinese Medicines, China Association  of Pharmaceutical Commerce, China Nonprescription Medicines Association, China  Pharmaceutical Enterprises Promotion Association and China Association of  Cultural Development of Pharmaceutical Companies jointly held the China Forum  on Ethical Business Practices for Pharmaceutical Industry. Leaders of the National  Family Planning Commission, China Food and Drug Administration and Ministry of  Industry and Information Technology attended the forum.

On October 29, 2013, the above nine associations  jointly held the Ceremony for Publishing Ethical Codes for Chinese  Pharmaceutical Companies, advocating compliance with the Codes within the  pharmaceutical industry. In this forum, representatives from these nine  associations exchanged experiences and understandings they obtained in the past  half year in promoting and implementing the Codes. The representatives took the  view that, promoting Codes to strengthen self-discipline of the pharmaceutical  industry and carrying out business under high ethical standards that are  transparent is an approach that will benefit multiple parties: for companies,  it can reduce operation costs and risks, especially for small and medium-sized enterprises;  for government, it will help with the creating of a sound industrial environment  and reducing regulatory challenges; and more importantly, it will help to  protect interests of patients. The Codes originated from the Codes of Business  Ethics in the Biopharmaceutical Sector (i.e. Mexico Principles) put forward by Asia-Pacific  Economic Cooperation (APEC) in September 2011 in Mexico. As China is hosting  APEC this year, further implementation of the Codes will have a greater  implication.  

On the other hand, patients,  healthcare professionals, drug-making industry and organizations will each play  a unique role in making appropriate diagnoses and treatments accessible to patients.  In January this year, the International Alliance of Patients’ Organizations  (IAPO), the International Council of Nurses (ICN), the International Federation  of Pharmaceutical Manufacturers and Associations (IFPMA), the International  Pharmaceutical Federation (FIP) and the World Medical Association (WMA) have  established a Consensus Framework for Ethical Collaboration between Patients’  Organizations, Healthcare Professionals and the Pharmaceutical Industry. This  framework is based on four overarching principles: putting patients first;  supporting ethical research and innovation; ensuring independence and ethical  conduct; and promoting transparency and accountability, which highlight the  best practices for cooperation among different organizations to promote patients’  health. In China, implementation of the Codes also relies on the jointly  efforts of the pharmaceutical industry, the drug-making industry, patients and the  government. The interests of patients could not be effectively protected and  the pharmaceutical industry could not develop soundly unless trust and respect  as well as common practices, rules and goals have been established among these  parties.


Leaders of Chinese Medical Association, Chinese  Pharmaceutical Association, Chinese Medical Doctor Association and Chinese Hospital  Association also attended the forum. 

Related articles: